Grifols has filed for US approval of a new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), which promises to provide a more reliable and easier treatment for patients.
The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almost $6 ...
After hours: February 3 at 5:37:30 p.m. EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback